- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02074007
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
January 23, 2017 updated by: Arbor Pharmaceuticals, Inc.
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Children ages 2 months to less than 19 years old, who have been diagnosed with a middle ear infection may receive either medicated ear drops (AR01) or glycerin (placebo) ear drops.
The patient or caregiver will measure the amount of ear pain before and after the ear drops to establish if the medicated ear drops decrease the amount of pain more than the placebo ear drops.
The subject may leave the clinic 60 minutes after the first dose.
The ear drops can be used up to 4 days, as needed for ear pain.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The study involves the initial clinic visit, using the ear drops at home and keeping a diary about the ear pain experienced and medications taken.
The patient will return to the clinic 4 days later for evaluation and to return the ear drops and diary.
The clinic staff will call to follow-up about the patient's condition seven days after the initial visit.
Study Type
Interventional
Enrollment (Actual)
178
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Clinical Research Consortium Arizona
-
-
California
-
Bakersfield, California, United States, 93301
- Kern Allergy and Medical Research, Inc
-
Fresno, California, United States, 93720
- Central California Research
-
-
Florida
-
Naples, Florida, United States, 34102
- Pharma Research International, Inc
-
St. Petersburg, Florida, United States, 33710
- SCORE Physician Alliance, LLC
-
-
Kentucky
-
Bardstown, Kentucky, United States, 40004
- Kentucky Pediatric / Adult Research
-
-
Nebraska
-
Bellevue, Nebraska, United States, 68005
- Pioneer Clinical Research, LLC
-
Omaha, Nebraska, United States, 68130
- Omaha ENT Clinic
-
-
New York
-
Utica, New York, United States, 13502
- Children's Health Center / St. Elizabeth Medical Center
-
Valley Stream, New York, United States, 11580
- Valley Stream Pediatrics
-
-
North Carolina
-
Clyde, North Carolina, United States, 39721
- Haywood pediatric and Adolescent Medicine Group, PA
-
-
Ohio
-
Cinncinati, Ohio, United States, 45246
- Sterling Research Group, Ltd
-
Columbus, Ohio, United States, 43207
- Central Ohio Clinical Research
-
Columbus, Ohio, United States, 43214
- Urgent Care Specialists Hometown Urgent Care
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- Carolina Ear, Nose & Throat Clinic
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- PMG Research of Bristol
-
Kingsport, Tennessee, United States, 37660
- Holston Medical Group
-
-
Utah
-
Layton, Utah, United States, 84041
- Tanner Clinic
-
Salt Lake City, Utah, United States, 84121
- Foothill Family Clinic South
-
Salt Lake City, Utah, United States, 84121
- Heartland Research Associates LLC - Augusta
-
-
Virginia
-
Alexandria, Virginia, United States, 22302
- Van Dorn Pediatrics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 months to 18 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects 2 mo. to < 19 yrs of age, with signs and symptoms of acute otitis media (AOM), with moderate to severe pain (current episode 2 wks duration). Moderate to severe pain is defined as a score of 5 (on a scale of 0 - 10) on the FAECC pain scale as evaluated by a trained clinical staff or 6 (on a scale of 0 - 10) on the FPS-R as evaluated by the subject. Moderate to severe pain criteria must be met at eligibility and the pre-dose pain assessment.
- Males or non-pregnant, non-lactating females.
- The subject's caregiver must have read and signed the written informed consent (including assent from subjects 18 yrs as applicable according to Investigational review board (IRB) guidelines) prior to study participation. Subjects 18 yrs old must have read and signed the written informed consent prior to study participation.
- Normally active and otherwise judged to be in good health on the basis of medical history and limited physical examination.
- Females of childbearing potential must have a urine pregnancy test at the randomization visit with negative results returned prior to randomization.
Exclusion Criteria
- Perforated tympanic membrane, history of a perforated tympanic membrane in the last 6 months, or if a perforated tympanic membrane could not be ruled out by speculum examination, impedance testing tympanometry, pneumatic otoscopy, or Valsalva maneuver. Subjects who are subsequently diagnosed with a perforated membrane during treatment are to be discontinued immediately. Subjects with tympanostomy tubes are not allowed.
- Acute or chronic otitis externa.
- Chronic otitis media (refers to current episode 2 wks).
- Seborrheic dermatitis involving the affected external ear canal or pinna.
- Any otic, topical, or systemic antibiotic received within 14 days prior to study entry (topical or systemic antibiotics for acne will be allowed on a chronic basis for subjects who have been on a stable dose for at least 14 days prior to entry).
- Any topical drying agent or over-the-counter therapy for otitis media received within 36 hrs prior to enrollment.
- Known hypersensitivity to drug or similar compounds including any of the inactive ingredients.
- Subjects receiving medication on a chronic basis for pain (including steroidal or non-steroidal anti-inflammatory drugs) who have not been on a stable dose for at least 1 month prior to entry into the study.
- Clinically significant mental illness that may interfere with the conduct of the study (determined by Investigator).
- Exposure to any investigational agent within 30 days prior to study entry.
- Previous enrollment in this study.
- Subject/caregiver has a condition the Investigator believes would interfere with the ability to provide consent or assent (age-appropriate) or comply with study instructions, or that might confound the interpretation of the study results, or put the subject at undue risk.
- Subject has a glucose 6-phosphate dehydrogenase deficiency or is taking concomitant medications associated with methemoglobinemia (such as nitrates or nitrites; aniline dyes; or medications, including lidocaine, prilocaine, phenazopyridine hydrochloride [Pyridium], and others).
- Subject shows clinical signs of anemia. The absolute amount of deoxygenated or abnormal hemoglobin (rather than its percentage) is required for cyanosis to be clinically evident. Subjects with moderate-to-severe anemia may not appear cyanotic, even with elevated percentages of deoxygenated or abnormal hemoglobins.
- Subject has congenital (i.e., hereditary) methemoglobinemia.
- Subject has a recent history of acute gastroenteritis within 14 days prior to study entry.
- Subject exhibits clinical signs of methemoglobinemia, such as unexplained bluish coloring of skin, fatigue, shortness of breath, failure to thrive, and headache.
- Subjects 5 to <19 yrs old who are unable to satisfactorily complete FPS-R screening test.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: AR01 - Topical Otic Solution
Topical ear drops The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period |
drops administered as needed for pain
Other Names:
|
PLACEBO_COMPARATOR: Placebo Comparator
Topical ear drops Glycerin ear drops-The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period. |
Glycerin ear drops (placebo) drops administered as needed for ear pain
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete ear pain relief
Time Frame: At or prior to 60 minutes post baseline dose
|
The proportion of subjects with complete pain relief (score of 0 on Face, Activity, Ears, Cry, Consolability tool (FAECC) as measured by the Assigned Clinical Assessor or Faces Pain Scale-Revised (FPS-R) as measured by the subject prior to any analgesic/antipyretic use) at or prior to 60 minutes post baseline dose.
|
At or prior to 60 minutes post baseline dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of subjects with complete ear pain relief
Time Frame: at or prior to 10, 20, 30, 45, and 60 minutes post baseline dose
|
The proportion of subjects with complete ear pain relief (score of 0 on FAECC or FPS-R prior to any analgesic/antipyretic use) at or prior to 10, 20, 30, 45, and 60 minutes post baseline dose.
|
at or prior to 10, 20, 30, 45, and 60 minutes post baseline dose
|
The percent change in FPS-R and FAECC pain scores from baseline to post dose scores
Time Frame: measured at 10, 20, 30, 45, and 60 minutes post baseline dose
|
measured at 10, 20, 30, 45, and 60 minutes post baseline dose
|
|
time to complete ear pain relief (score of 0 on pain scales)
Time Frame: 10, 20, 30, 45, and 60 minutes post baseline dose
|
The time to complete pain relief (score of 0 on FAECC or FPS-R prior to any analgesic/antipyretic use), in minutes.
|
10, 20, 30, 45, and 60 minutes post baseline dose
|
Sum of pain intensity differences (SPID) using FPS-R and FAECC pain scores
Time Frame: scores at pre-dose and 60 minutes post dose
|
scores at pre-dose and 60 minutes post dose
|
|
Time from baseline to in-clinic use of analgesic/antipyretic to relief ear pain
Time Frame: 60 minutes
|
60 minutes
|
|
The number of subjects who receive analgesic/antipyretic medications for relief of ear pain during the clinic visit
Time Frame: measured at or prior to 10, 20, 30, 45, and 60 minutes post baseline
|
measured at or prior to 10, 20, 30, 45, and 60 minutes post baseline
|
|
Number of adverse events reported as a measure of safety and tolerability
Time Frame: up to 30 days
|
up to 30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time from complete ear pain relief (score of 0 on FAECC or FPS-R) to a pain event using the home use data
Time Frame: up to 4 Days (± 1)
|
A pain event may include any or all of the following: analgesic/antipyretic use, a FAECC score ≥5 or FPS-R score ≥6, and study withdrawal due to AOM, treatment, or the study itself.
|
up to 4 Days (± 1)
|
Relation between Analgesic/antipyretic use and study medication use during the In-Home Use period at or prior to 15, 30, and 60 minutes
Time Frame: at or prior to 15, 30, and 60 minutes baseline study medication dose and up to 4 Days (± 1)
|
Dates and times of analgesic/antipyretic use from will be compared with the dates and times of home use of study medication to create the use or non-use outcome for each time point.
|
at or prior to 15, 30, and 60 minutes baseline study medication dose and up to 4 Days (± 1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Laurence J Downey, MD, Arbor Pharmaceuticals, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (ACTUAL)
June 1, 2014
Study Completion (ACTUAL)
June 1, 2014
Study Registration Dates
First Submitted
January 16, 2014
First Submitted That Met QC Criteria
February 26, 2014
First Posted (ESTIMATE)
February 28, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
January 24, 2017
Last Update Submitted That Met QC Criteria
January 23, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AR01.007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Otitis Media
-
AcclarentCompletedRecurrent Acute Otitis Media | Acute Otitis Media | Chronic Otitis MediaUnited States
-
David Chi, MDRecruitingRecurrent Acute Otitis Media | Chronic Otitis Media With Effusion | Otitis Media in ChildrenUnited States
-
Medical College of WisconsinNational Institutes of Health (NIH); National Institute on Deafness and Other... and other collaboratorsRecruitingOtitis Media | Otitis Media With Effusion | Otitis Media AcuteUnited States
-
Tusker MedicalCompletedAOM - Acute Otitis Media | OME - Otitis Media With EffusionUnited States, Canada
-
Smith & Nephew, Inc.RecruitingOtitis Media | Otitis Media With Effusion | Acute Otitis MediaUnited States
-
AcclarentCompletedOtitis Media With Effusion | Acute Otitis MediaUnited States
-
Rochester General HospitalActive, not recruitingDynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens (AOM)Acute Otitis MediaUnited States
-
University of OuluOulu University HospitalCompletedAcute Otitis MediaFinland
-
University of WashingtonStandard Homeopathic CompanyCompleted
-
PfizerCompletedAcute Otitis MediaCosta Rica
Clinical Trials on AR01
-
Arbor Pharmaceuticals, Inc.CompletedPain | Otitis MediaUnited States
-
Arbor Pharmaceuticals, Inc.CompletedAcute Otitis MediaUnited States